Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
Conversion surgery after meeting the surgical criteria during immunotherapy provides significant prognostic benefits for patients with initially unresectable HCC, demonstrating high safety and R0 resection rates. For those undergoing conversion surgery, promptly resuming the original treatment after surgery is necessary.
Authors
- Shuofeng Li (ORCID: https://orcid.org/0000-0002-6033-6476)
- Yang Xu (ORCID: https://orcid.org/0000-0001-7172-5277)
- Nan Zhang (ORCID: https://orcid.org/0000-0001-7608-8561)
- Ziyue Huang (ORCID: https://orcid.org/0000-0001-7336-7370)
- Ziyu Xun
- Faming Zhang (ORCID: https://orcid.org/0000-0003-4157-1144)
- Boyu Sun
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-4728-0180)
- Shanshan Wang (ORCID: https://orcid.org/0000-0002-6651-2821)
- Li Zhang (ORCID: https://orcid.org/0000-0002-3617-2627)
- Chengjie Li
- Xiaobo Yang (ORCID: https://orcid.org/0000-0001-9866-7724)
- Mingjian Piao (ORCID: https://orcid.org/0009-0005-4981-5942)
- Jiongyuan Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1159/000543994
- Citations
- 5
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 6.61
Funders
- Peking Union Medical College Hospital
- Chinese Society of Clinical Oncology
- National Ten Thousand Talent Program